Gilead Advances HIV PrEP Partnerships — GILD

Gilead's filing of an NDA for lenacapavir as a once-yearly HIV PrEP option, together with an ongoing Phase 3 oral combination program with bictegravir, positions the company to expand its prevention franchise beyond existing single-tablet regimens. For investors, the regulatory pathway for a long-acting capsid inhibitor could broaden addressable markets in HIV prevention and complement treatment staples such as Biktarvy, which remains a leading revenue contributor. The company's collaboration framework — including programs with Merck on integrase inhibitor combinations — underlines a strategic approach to accelerate clinical development and leverage external expertise. Existing long-term collaboration structures (for example, multi-year opt-in arrangements with partners such as Arcus and Galapagos) demonstrate Gilead's preference for flexible alliances that can scale if clinical data and regulatory traction materialize.

HIV products dominate Gilead's top-line: Biktarvy alone accounted for $3.15 billion in Q1 2025 product sales, and aggregate product sales were $6.613 billion for the period referenced. The U.S. market represents roughly 70% of product sales, highlighting the importance of U.S. regulatory outcomes and payer dynamics to commercial success. From a moat perspective, Gilead benefits from patent protection and switching costs tied to effective single-tablet regimens, but these advantages are finite and dependent on continued patent life and clinical differentiation. The company's intangible asset base (for example, sofosbuvir-related carrying value reported in disclosures) and ongoing amortization underline the capitalized nature of past acquisitions and in‑licensed technologies. Investors should weigh potential upside from a successful lenacapavir approval against the company's existing amortization and IPR&D exposures.

Regulatory outcomes remain the primary near-term risk: lenacapavir's NDA is pending and approval is not guaranteed. The company also faces standard pharmaceutical risks such as product liability litigation, potential clinical setbacks (notably, prior pipeline adjustments have occurred), and pricing/reimbursement pressures in the U.S. where the majority of sales are concentrated. Operational execution of partner programs is another watch item. While collaborations can accelerate development, they also introduce dependency on third-party decisions and opt-in economics, which affect both timing and ultimate value capture for shareholders.